Somatic mutations, acetylator status, and prognosis in colorectal cancer

Gut

Volumn 42, Issue 5, 1998, Pages 669-672

  Hardingham, J E ^a   Butler, W J ^a   Roder, D ^b   Dobrovic, A ^a   Dymock, R B ^a   Sage, R E ^a   Roberts Thomson, I C ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b South Australian Health Commission   (Australia)

Author keywords

Acetylator status; Colorectal cancer; Prognosis; TP53 and K ras mutations

Indexed keywords

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL RATE;

EID: 0031811341     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.42.5.669     Document Type: Article

References (27)

1. Cohen AM, Minsky BD, Schilsky RL. Cancer of the colon. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles and practice of oncology. Philadelphia: Lippincott-Raven Publishers, 1997:1144-97.
2. Starzynska T, Bromley M, Ghosh A, et al. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
3. Nathanson SD, Linden MD, Tender P, et al. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum 1994;37:527-34.
4. Goh H-S, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.
5. Miyahara M, Saito T, Kaketani K, et al. Clinical significance of ras p21 overexpression for patients with an advanced colorectal cancer. Dis Colon Rectum 1991;34:1097-102.
6. Benhattar J, Losi L, Chaubert P, et al. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044-8.
7. Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
8. Markowitz S, Hines JD, Lutterbaugh J, et al. Mutant K-ras oncogenes in colon cancers do not predict patient's chemotherapy response or survival. Clin Cancer Res 1195;1:441-5.
9. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
10. Roberts-Thomson IC, Ryan P, et al. Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet 1996;347: 1372-4.
11. Oda Y, Tanaka M, Nakanishi I. Relation between the occurrence of K-ras gene point mutations and genotypes of polymorphic N-acetyltransferase in human colorectal carcinomas. Carcinogenesis 1994;15:1365-9.
12. Hardingham JE, Kotasek D, Farmer B, et al. Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic heads and the polymerase chain reaction. Cancer Res 1993;53:3455-8.
13. Bassam BJ, Caetano-Anolles G, Gresshoff PM. Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem 1991;196:80-3.
14. Hickman D, Sim E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 1991;42:1007-14.
15. Shepherd NA. Pathological prognostic factors in colorectal cancer. In: Kirkham N, Lemoine NR, eds. Progress in pathology. Vol 2. Edinburgh: Churchill Livingstone, 1995: 115-41.
16. Bonett A, Roder D, Esterman A. Cancer case-survival rates for South Australia: a comparison with US rates and a preliminary investigation of time trends. Med J Aust 1988;148: 556-9.
17. South Australian Cancer Registry. Epidemiology of cancer in South Australia. Incidence, mortality and survival, 1977 to 1996. Incidence and mortality, 1996. Adelaide: Openbook Publishers, 1997.
18. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific Publications, 1988:421-39.
19. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987, 327:293-7.
20. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
21. Hollstein M, Sidransky D, Vogelstein B, et al. P53 mutations in human cancers. Science 1991;253:49-53.
22. Minchin RF, Kadlubar FF, Ilett KF. Role of acetylation in colorectal cancer. Mutation Res 1993;290:35-42.
23. Kakiuchi H, Watanabe M, Ushijima T, et al. Specific 5′-GGGA-3′ to 5′-GGA-3′ mutation of the Apc gene in rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Proc Natl Acad Sci USA 1995;92:910-4.
24. Freedman LS. Tables of the number of patients required in clinical trials using the log rank test. Stat Med 1982;1:121-9.
25. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol 1992;166:329-30.
26. Remvikos Y, Laurent-Puig P, Salmon RJ, et al. Simultaneous monitoring of p5 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer 1990;45: 450-6.
27. Lowe SW, Ruley HE, Jacks T, et al. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.